Milestone Pharmaceuticals: Interesting, But Not Well-Differentiated From Generic Competition [Seeking Alpha]
Milestone Pharmaceuticals Inc. - Common Shares (MIST)
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Milestone Pharmaceuticals: Interesting, But Not Well-Differentiated From Generic Competition Summary MIST is a recent IPO specialising in CV drugs. Its lead drug Etripamil is targeting Paroxysmal supraventricular tachycardia, a pretty decent-sized market. However, the L-type channel blocker drug is not differentiated enough from competition. Very few drugs are available for the cardiovascular sector, and even fewer companies actually develop a specialty focus in this area. Milestone Pharmaceuticals ( The disease and the science Paroxysmal supraventricular tachycardia or PSVT is a type of supraventricular tachycardia. That means, electric pulses in the heart’s upper chambers do not work properly, and the heart beats too fast to properly fill in blood. may often not have symptoms for PSVT. Symptoms, when they occur, may include “palpitations, feeling lightheaded, sweating, shortness of breath, and chest pain.” Paroxysmal means episodic, and these occur and end suddenly, are generally i
Show less
Read more
Impact Snapshot
Event Time:
MIST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIST alerts
High impacting Milestone Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MIST
News
- After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright [Yahoo! Finance]Yahoo! Finance
- Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update [Yahoo! Finance]Yahoo! Finance
- Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate UpdateGlobeNewswire
- Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.MarketBeat
- Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46% [Yahoo! Finance]Yahoo! Finance
MIST
Earnings
- 11/12/24 - Beat
MIST
Analyst Actions
- 10/14/24 - HC Wainwright
MIST
Sec Filings
- 11/12/24 - Form S-3
- 11/12/24 - Form S-8
- 11/12/24 - Form 8-K
- MIST's page on the SEC website